Sophie Desmonde, Joycelyn Dame, Karen Malateste, Agatha David, Madeleine Amorissani-Folquet, Sylvie N'Gbeche, Mariam Sylla, Elom Takassi, Kouadio Kouakou, Lehila Bagnan Tossa, Caroline Yonaba, Valériane Leroy
INTRODUCTION: We describe the incidence of Dolutegravir (DTG)-containing antiretroviral treatment (ART) initiation since its introduction in 2019 in pediatric West African IeDEA cohorts. METHODS: We included all patients aged 0-24 years on ART, from nine clinics in Côte d'Ivoire (n=4), Ghana, Nigeria, Mali, Benin, and Burkina Faso. Baseline varied by site and was defined as date of first DTG prescription; patients were followed-up until database closure/death/loss to follow-up (LTFU, no visit ≥ 7 months), whichever came first...
May 25, 2024: medRxiv